BACKGROUND: Neuraminidase-1 (NEU1) catabolizes the hydrolysis of sialic acids from sialo-glycoconjugates. NEU1 depends on its interaction with the protective protein/cathepsin A (PPCA) for lysosomal compartmentalization and catalytic activation. Murine NEU1 contains 4 N-glycosylation sites, 3 of which are conserved in the human enzyme. The expression of NEU1 gives rise to differentially glycosylated proteins. METHODS: We generated single-point mutations in mouse NEU1 at each of the 4 N-glycosylation sites. Mutant enzymes were expressed in NEU1-deficient cells in the presence and absence of PPCA. RESULTS: All 4 N-glycosylation variants were targeted to the lysosomal/endosomal compartment. All N-glycans, with the exception of the most C-terminal glycan, were important for maintaining stability or catalytic activity. The loss of catalytic activity caused by the deletion of the second N-glycan was rescued by increasing PPCA expression. Similar results were obtained with a human NEU1 N-glycosylation mutant identified in a sialidosis patient. The N-terminal N-glycan of NEU1 is indispensable for its function, whereas the C-terminal N-glycan appears to be non-essential. The omission of the second N-glycan can be compensated for by upregulating the expression of PPCA. GENERAL SIGNIFICANCE: These findings could be relevant for the design of target therapies for patients carrying specific NEU1 mutations.
BACKGROUND:Neuraminidase-1 (NEU1) catabolizes the hydrolysis of sialic acids from sialo-glycoconjugates. NEU1 depends on its interaction with the protective protein/cathepsin A (PPCA) for lysosomal compartmentalization and catalytic activation. Murine NEU1 contains 4 N-glycosylation sites, 3 of which are conserved in the human enzyme. The expression of NEU1 gives rise to differentially glycosylated proteins. METHODS: We generated single-point mutations in mouseNEU1 at each of the 4 N-glycosylation sites. Mutant enzymes were expressed in NEU1-deficient cells in the presence and absence of PPCA. RESULTS: All 4 N-glycosylation variants were targeted to the lysosomal/endosomal compartment. All N-glycans, with the exception of the most C-terminal glycan, were important for maintaining stability or catalytic activity. The loss of catalytic activity caused by the deletion of the second N-glycan was rescued by increasing PPCA expression. Similar results were obtained with a humanNEU1 N-glycosylation mutant identified in a sialidosispatient. The N-terminal N-glycan of NEU1 is indispensable for its function, whereas the C-terminal N-glycan appears to be non-essential. The omission of the second N-glycan can be compensated for by upregulating the expression of PPCA. GENERAL SIGNIFICANCE: These findings could be relevant for the design of target therapies for patients carrying specific NEU1 mutations.
Authors: Thasia Leimig; Linda Mann; Maria del Pilar Martin; Erik Bonten; Derek Persons; James Knowles; James A Allay; John Cunningham; Arthur W Nienhuis; Richard Smeyne; Alessandra d'Azzo Journal: Blood Date: 2002-05-01 Impact factor: 22.113
Authors: Natalie de Geest; Erik Bonten; Linda Mann; Jean de Sousa-Hitzler; Christopher Hahn; Alessandra d'Azzo Journal: Hum Mol Genet Date: 2002-06-01 Impact factor: 6.150
Authors: Kerry Gordon; Pierre Redelinghuys; Sylva L U Schwager; Mario R W Ehlers; Anastassios C Papageorgiou; Ramanathan Natesh; K Ravi Acharya; Edward D Sturrock Journal: Biochem J Date: 2003-04-15 Impact factor: 3.857
Authors: Prajnya Ranganath; Vishakha Sharma; Sumita Danda; Madhusudan R Nandineni; Ashwin B Dalal Journal: Indian J Med Res Date: 2012-12 Impact factor: 2.375